Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
This unique record was made possible by collating hard copies of the books in a structured manner
Key takeaways of recent quarter & conference call highlights
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
The company claims that its Empagliflozin tablets are the most affordable in India
Equity raise to finance growth and investments in the biological space
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
Subscribe To Our Newsletter & Stay Updated
